secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUTRO BIOPHARMA, INC. (STRO)
CIK:        0001382101
Form:       8-K
Filed at:   2024-03-25T23:59:59+00:00
Accession:  0000950170-24-035948
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sutro Biopharma reports FY2023 revenue of $153.7M and $333.7M cash, runway into H2 2025
--------------------------------------------------------------------------------

- Revenue $153.7M in FY2023 vs $67.8M in FY2022, driven by Vaxcyte option exercise and collaborations.
- Cash and investments $333.7M plus Vaxcyte stock valued at $41.9M, providing runway into H2 2025.
- Total operating expenses $243.0M; R&D $180.4M, G&A $62.6M; includes stock-based comp $24.9M, D&A $6.8M.
- Jane Chung promoted to President and COO; enrollment in REFRαME-O1 for PROC ongoing, Part 1 expected complete H1 2024.
- Vaxcyte paid $50M for manufacturing rights option, with additional $25M due within six months and up to $60M milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024035948/0000950170-24-035948-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382101/000095017024035948/stro-20240325.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-035948

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer